MA56129A - Procédés de production d'un anticorps anti-alpha4béta7 - Google Patents
Procédés de production d'un anticorps anti-alpha4béta7Info
- Publication number
- MA56129A MA56129A MA056129A MA56129A MA56129A MA 56129 A MA56129 A MA 56129A MA 056129 A MA056129 A MA 056129A MA 56129 A MA56129 A MA 56129A MA 56129 A MA56129 A MA 56129A
- Authority
- MA
- Morocco
- Prior art keywords
- antibody
- producing
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962859494P | 2019-06-10 | 2019-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA56129A true MA56129A (fr) | 2022-04-13 |
Family
ID=73781728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA056129A MA56129A (fr) | 2019-06-10 | 2020-06-10 | Procédés de production d'un anticorps anti-alpha4béta7 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220267449A1 (fr) |
EP (1) | EP3980466A4 (fr) |
JP (1) | JP2022536486A (fr) |
CN (1) | CN114375307A (fr) |
AR (1) | AR119270A1 (fr) |
AU (1) | AU2020290943A1 (fr) |
BR (1) | BR112021024897A2 (fr) |
CA (1) | CA3143167A1 (fr) |
IL (1) | IL288825A (fr) |
MA (1) | MA56129A (fr) |
MX (1) | MX2021015300A (fr) |
PL (1) | PL439809A1 (fr) |
TW (1) | TW202112818A (fr) |
WO (1) | WO2020252069A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202009872YA (en) * | 2018-04-10 | 2020-11-27 | Dr Reddys Laboratories Ltd | Stable antibody formulation |
WO2023007516A1 (fr) * | 2021-07-29 | 2023-02-02 | Dr. Reddy’S Laboratories Limited | Procédé de régulation d'agrégats de poids moléculaire élevé dans une composition d'anticorps |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5429746A (en) * | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
WO2014142882A1 (fr) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Purification de protéine utilisant une chromatographie de déplacement |
MA41636A (fr) * | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
-
2020
- 2020-06-10 MA MA056129A patent/MA56129A/fr unknown
- 2020-06-10 BR BR112021024897A patent/BR112021024897A2/pt unknown
- 2020-06-10 JP JP2021573298A patent/JP2022536486A/ja active Pending
- 2020-06-10 AU AU2020290943A patent/AU2020290943A1/en active Pending
- 2020-06-10 TW TW109119563A patent/TW202112818A/zh unknown
- 2020-06-10 PL PL439809A patent/PL439809A1/pl unknown
- 2020-06-10 CN CN202080049572.2A patent/CN114375307A/zh active Pending
- 2020-06-10 CA CA3143167A patent/CA3143167A1/fr active Pending
- 2020-06-10 MX MX2021015300A patent/MX2021015300A/es unknown
- 2020-06-10 AR ARP200101641A patent/AR119270A1/es unknown
- 2020-06-10 WO PCT/US2020/037059 patent/WO2020252069A1/fr unknown
- 2020-06-10 EP EP20822340.4A patent/EP3980466A4/fr active Pending
- 2020-06-10 US US17/596,421 patent/US20220267449A1/en active Pending
-
2021
- 2021-12-09 IL IL288825A patent/IL288825A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021024897A2 (pt) | 2022-01-18 |
EP3980466A1 (fr) | 2022-04-13 |
CN114375307A (zh) | 2022-04-19 |
JP2022536486A (ja) | 2022-08-17 |
IL288825A (en) | 2022-02-01 |
EP3980466A4 (fr) | 2023-06-07 |
MX2021015300A (es) | 2022-02-03 |
AU2020290943A1 (en) | 2022-02-03 |
CA3143167A1 (fr) | 2020-12-17 |
TW202112818A (zh) | 2021-04-01 |
AR119270A1 (es) | 2021-12-09 |
PL439809A1 (pl) | 2022-12-05 |
US20220267449A1 (en) | 2022-08-25 |
WO2020252069A1 (fr) | 2020-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49034B1 (fr) | Anticorps anti-lag3 | |
MA48723A (fr) | Procédé de production d'anticorps multispécifiques | |
MA52742A (fr) | Anticorps bispécifiques dll3-cd3 | |
MA55363A (fr) | Anticorps multispécifiques egfr x cd28 | |
MA50505A (fr) | Anticorps 2 + 1 bispécifiques (contorsbodies) | |
MA49394A (fr) | Procédé de fabrication d'anticorps bispécifiques, anticorps bispécifiques et utilisation thérapeutique desdits anticorps | |
MA53434A (fr) | Anticorps anti-tigit | |
MA42924A (fr) | Variants optimisés d'anticorps anti-vegf | |
MA43956A (fr) | Constructions d'anticorps bispécifiques d'engagement avec les cellules t | |
MA43197A (fr) | Constructions d'anticorps bispécifiques pour cdh3 et cd3 | |
MA50169A (fr) | Procédé de production d'un électrocatalyseur | |
MA47494A (fr) | Nouvelles utilisations d'anticorps anti-sirpg | |
MA53920A (fr) | Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38 | |
MA54090A (fr) | Production enzymatique d'hexoses | |
MA51417A (fr) | Constructions d'anticorps bispécifiques dirigés contre muc17 et cd3 | |
MA53445A (fr) | Procédés et compositions pour la modification de plantes | |
MA56129A (fr) | Procédés de production d'un anticorps anti-alpha4béta7 | |
IT201700063208A1 (it) | Metodo per la produzione di aggregati dal calcestruzzo reso | |
MX2021007119A (es) | Metodos para producir anticuerpos heterodimericos. | |
DK3749668T3 (da) | Kontinuerlig fremgangsmåde til fremstilling af trazodonbase | |
EA202091259A1 (ru) | Способ получения опикапона и его интермедиатов | |
MA56466A (fr) | Anticorps anti-epha4 | |
MA55284A (fr) | Procédés de production de compositions d'anticorps anti-tnf | |
IL290825A (en) | Methods for producing antibody preparations | |
MA45831A (fr) | Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation |